MarketLens

Is Rhythm Pharmaceuticals Poised for a Breakthrough in Hypothalamic Obesity

5 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is Ionis Pharmaceuticals Poised for a Breakthrough with Tryngolza

5 months ago

What Does the FDA's PDUFA Extension Signal for Rhythm Pharmaceuticals

5 months ago

Is TeraDrill (TDRL) Poised for a Breakthrough in Mining Automation

3 months ago

Is EcoSolutions Waste Poised for a Biofuel Breakthrough

5 months ago

Amylyx Pharmaceuticals: Avexitide Defines The Endocrine Rebuild

Amylyx Pharmaceuticals is pivoting to endocrine care, with avexitide targeting post-bariatric hypoglycemia. Its $250.8M cash runway funds the LUCIDITY Phase 3 readout and potential 2027 launch, with t...

AMLX

Stock News•1 week ago

Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition

Rhythm Pharmaceuticals' experimental weekly injectable reduced body weight in patients with a rare obesity form caused by brain damage, per preliminary mid-stage data released Tuesday.

RYTM

Stock News•2 months ago

Kalohexis Announces Publication in Nature Communications Highlighting Dual MC3R/MC4R Activation as a Novel, Durable Mechanism that Drives Weight Loss

Kalohexis published findings in Nature Communications demonstrating that dual MC3R/MC4R activation drives durable weight loss. This mechanism could position the company's metabolic pipeline as a diffe...

Stock News•3 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Rhythm Pharmaceuticals (RYTM) management discussed operational progress and strategic outlook at the 2026 Bank of America Global Healthcare Conference. The presentation provided updates on the company...

RYTM